Kyverna Therapeutics Inc (KYTX)

Dec 04, 2025

Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks

Dec 04, 2025

Dec 04, 2025

Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser

Dec 04, 2025

Dec 04, 2025

Published on: 2025-12-04 05:07:23 - Newser

Dec 04, 2025

Dec 03, 2025

How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser

Dec 03, 2025

Dec 03, 2025

Kyverna Therapeutics Inc Stock Analysis and ForecastShort Interest Overview & High Yield Trading Alerts - earlytimes.in

Dec 03, 2025

Dec 02, 2025

IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ

Dec 02, 2025

Dec 01, 2025

6 Companies Hanging On in Cell Therapy - BioSpace

Dec 01, 2025

Nov 27, 2025

Aug Gainers: What margin trends mean for Kyverna Therapeutics Inc. stock2025 Key Lessons & Real-Time Chart Pattern Alerts - BỘ NỘI VỤ

Nov 27, 2025

Nov 27, 2025

FY2025 Earnings Estimate for KYTX Issued By HC Wainwright - MarketBeat

Nov 27, 2025

Nov 27, 2025

Trend Recap: Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Setups & Long-Term Capital Growth Strategies - BỘ NỘI VỤ

Nov 27, 2025

Nov 24, 2025

Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases - TipRanks

Nov 24, 2025

Nov 21, 2025

Why Kyverna Therapeutics Inc. stock remains resilient2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com

Nov 21, 2025

Nov 19, 2025

How sentiment analysis helps forecast Kyverna Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com

Nov 19, 2025

Nov 19, 2025

Why Kyverna Therapeutics Inc. stock remains undervaluedJuly 2025 Fed Impact & Daily Stock Trend Reports - newser.com

Nov 19, 2025

Nov 19, 2025

Is Kyverna Therapeutics Inc. stock attractive for passive investorsWeekly Profit Summary & Verified Entry Point Signals - newser.com

Nov 19, 2025

Nov 17, 2025

TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX) - Seeking Alpha

Nov 17, 2025

Nov 17, 2025

KYTX: KYV-101 delivers transformative results in autoimmune diseases, targeting first-to-market leadership - TradingView

Nov 17, 2025

Nov 17, 2025

KYTX: KYV101 demonstrates transformative efficacy and safety in autoimmune diseases, targeting first-to-market leadership - TradingView

Nov 17, 2025

Nov 16, 2025

Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com

Nov 16, 2025

Nov 15, 2025

What analysts say about Kyverna Therapeutics Inc stockVWAP Trading Strategies & Calculate Profit Targets With AI Accuracy - earlytimes.in

Nov 15, 2025

Nov 15, 2025

What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com

Nov 15, 2025

Nov 14, 2025

Myasthenia Gravis Market is expected to grow at a CAGR of 10.4% by 2034, estimates DelveInsight - Barchart.com

Nov 14, 2025

Nov 14, 2025

What analyst consensus says on Kyverna Therapeutics Inc. stockJuly 2025 Update & Stepwise Trade Signal Guides - Fundação Cultural do Pará

Nov 14, 2025

Nov 14, 2025

Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential - Seeking Alpha

Nov 14, 2025

Nov 14, 2025

Combining price and volume data for Kyverna Therapeutics Inc.Trade Analysis Summary & Detailed Earnings Play Alerts - newser.com

Nov 14, 2025

Nov 13, 2025

Kyverna Therapeutics (NASDAQ:KYTX) Issues Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat

Nov 13, 2025